Published in Transfusion on November 23, 2010
Efficacy and side effects of granulocyte collection in healthy donors. Transfus Med Hemother (2013) 0.83
Concise review: next-generation cell therapies to prevent infections in neutropenic patients. Stem Cells Transl Med (2014) 0.75
Cataracts and corticosteroids in granulocyte donors. Transfusion (2011) 0.75
The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials (1999) 6.24
The Lens Opacities Case-Control Study. Risk factors for cataract. Arch Ophthalmol (1991) 4.93
Sunlight exposure and risk of lens opacities in a population-based study: the Salisbury Eye Evaluation project. JAMA (1998) 3.08
The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol (2001) 2.29
The epidemiology of cataract in Australia. Am J Ophthalmol (1999) 2.01
Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology (1997) 1.79
The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion (2005) 1.52
The etiology of steroid cataract. J Ocul Pharmacol Ther (2007) 1.47
Risk factors for age-related cataracts. Epidemiol Rev (1995) 1.39
An exact trend test for correlated binary data. Biometrics (2001) 1.13
Prevalence of lens opacities in surgical and general populations. Arch Ophthalmol (1991) 1.08
Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci (2008) 1.03
Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group. Ophthalmology (1997) 1.01
Contrast acuity in cataracts of different morphology and association to self-reported visual function. Invest Ophthalmol Vis Sci (2006) 0.99
Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion (2001) 0.98
Assessment of ocular exposure to ultraviolet-B for population studies. Salisbury Eye Evaluation Project Team. Photochem Photobiol (1997) 0.91
Risk factors for cortical, nuclear, posterior subcapsular and mixed cataract: a case-control study. Ophthalmic Epidemiol (1994) 0.89
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med (2007) 5.18
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Age-related macular degeneration. Lancet (2008) 3.34
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology (2005) 3.28
Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol (2009) 3.21
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
Prevalence of refractive error in the United States, 1999-2004. Arch Ophthalmol (2008) 3.06
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol (2007) 3.02
Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med (2011) 2.98
Diabetic retinopathy. Diabetes Care (2004) 2.97
Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2004) 2.65
Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008. JAMA (2012) 2.36
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol (2007) 2.12
The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology (2004) 2.01
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood (2009) 1.96
The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol (2008) 1.93
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol (2011) 1.75
Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol (2004) 1.69
Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. Ophthalmology (2008) 1.69
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology (2012) 1.66
Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol (2004) 1.63
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology (2007) 1.59
Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol (2005) 1.58
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci (2008) 1.58
Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome. Transfusion (2013) 1.53
Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol (2009) 1.53
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology (2011) 1.52
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci U S A (2006) 1.52
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood (2012) 1.51
Vitreous cytokine levels. Ophthalmology (2003) 1.48
An electronic medical records system for clinical research and the EMR EDC interface. Invest Ophthalmol Vis Sci (2007) 1.48
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (2007) 1.46
Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion (2003) 1.45
{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr (2009) 1.44
Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol (2005) 1.41
Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood (2009) 1.40
The value of pH as a quality control indicator for apheresis platelets. Transfusion (2005) 1.38
Agreement among glaucoma specialists in assessing progressive disc changes from photographs in open-angle glaucoma patients. Am J Ophthalmol (2008) 1.37
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes (2004) 1.35
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care (2005) 1.34
Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood (2002) 1.32
Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology (2010) 1.32
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol (2013) 1.31
Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina (2010) 1.30
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology (2003) 1.30
G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion (2003) 1.29
Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep (2012) 1.28
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood (2008) 1.28
Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood (2002) 1.27
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol (2002) 1.24
Clinical detection of precataractous lens protein changes using dynamic light scattering. Arch Ophthalmol (2008) 1.23
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci (2004) 1.20
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
Iron replacement therapy in the routine management of blood donors. Transfusion (2011) 1.20
Mitochondrial DNA variants of respiratory complex I that uniquely characterize haplogroup T2 are associated with increased risk of age-related macular degeneration. PLoS One (2009) 1.19
Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology (2010) 1.18
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17
The LOC387715 polymorphism and age-related macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci (2007) 1.17
Astigmatism outcomes of horizontal temporal versus nasal clear corneal incision cataract surgery. J Cataract Refract Surg (2004) 1.16
Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina (2006) 1.13
Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion (2002) 1.13
Use of an arginine-restricted diet to slow progression of visual loss in patients with gyrate atrophy. Arch Ophthalmol (2004) 1.12
Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration. Transfusion (2004) 1.12
Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology (2011) 1.12
Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion (2008) 1.11
Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol (2007) 1.11
Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology (2003) 1.11